Studies examining the procoagulant effects of cell-free DNA on coagulation in vitro
| Reference . | Cellular origin . | Method of purification . | Coagulation Assay . | Type of DNA . | Conclusions . |
|---|---|---|---|---|---|
| Kannemeier et al 200752 | China Hamster ovarian cell line | Silica-based affinity chromatography | Thromboelastography | Genomic | DNA shortens clotting times in whole blood and plasma, activates FXII and amplifies thrombin-dependent FXIa generation in buffer |
| Clotting times in plasma | |||||
| Chromogenic assay in plasma | |||||
| Chromogenic assay in purified system | |||||
| Oemcke et al 200953 | Normal human neutrophils | Guanidinium isothiocyanate detergent + ethanol precipitation | Chromogenic assay for PK hydrolysis in plasma | Genomic | DNA binds FXII and HK and promotes PK hydrolysis in plasma |
| Swystun et al 201154 | Chemotherapy-treated normal whole blood or neutrophils | Silica-based affinity chromatography | Thrombin generation in PPP | Genomic | Extracellular DNA released from chemotherapy-treated blood cells increases thrombin generation in plasma |
| Vu et al 201555 | A549 cells | Silica-based affinity chromatography | Clotting times in plasma | Genomic | DNA shortens clotting times, increases TG in plasma, promotes FXII activation and FXIa generation in buffer |
| Thrombin generation in PPP | |||||
| FXII activation, FXIIa-dependent and thrombin-dependent FXIa generation in purified systems | |||||
| Bhagirath et al 201556 | HEK297 cells | Silica-based affinity chromatography. | Thrombin generation in PPP | Genomic | All types of DNA enhance TG in plasma |
| Bacteria | Bacterial DNA was purchased. | Mitochondrial | |||
| Bacterial | |||||
| Kokoye et al 201614 | Normal human leukocytes | Phenol-chloroform extraction | Western blot for FXII and PK activation in purified systems | Genomic | DNA enhances FXII and PK activation in buffer and enhances thrombin generation in plasma. |
| Thrombin generation in PPP | |||||
| Noubouossie et al 201724 | Normal human neutrophils | Silica-based affinity chromatography | ELISA for FXIa-C1INH complexes in purified contact system | Genomic | DNA triggers contact activation in buffer and thrombin generation in PFP and PRP |
| Chromogenic assays for FXIa generation in buffer | DNA amplifies FXIIa- and thrombin-dependent FXIa generation in buffer | ||||
| Thrombin generation in PFP or PRP | DNA amplifies TF-initiated TG in plasma | ||||
| Ivanov et al 201757 | Normal human leukocytes | Phenol-chloroform extraction | Chromogenic assays for PK and FXI activation | Genomic | DNA promotes PK (in the presence of HK) and FXI activation |
| Thrombin generation in plasma | DNA initiates thrombin generation in plasma independently of TF, and amplifies TF-initiated TG in plasma |
| Reference . | Cellular origin . | Method of purification . | Coagulation Assay . | Type of DNA . | Conclusions . |
|---|---|---|---|---|---|
| Kannemeier et al 200752 | China Hamster ovarian cell line | Silica-based affinity chromatography | Thromboelastography | Genomic | DNA shortens clotting times in whole blood and plasma, activates FXII and amplifies thrombin-dependent FXIa generation in buffer |
| Clotting times in plasma | |||||
| Chromogenic assay in plasma | |||||
| Chromogenic assay in purified system | |||||
| Oemcke et al 200953 | Normal human neutrophils | Guanidinium isothiocyanate detergent + ethanol precipitation | Chromogenic assay for PK hydrolysis in plasma | Genomic | DNA binds FXII and HK and promotes PK hydrolysis in plasma |
| Swystun et al 201154 | Chemotherapy-treated normal whole blood or neutrophils | Silica-based affinity chromatography | Thrombin generation in PPP | Genomic | Extracellular DNA released from chemotherapy-treated blood cells increases thrombin generation in plasma |
| Vu et al 201555 | A549 cells | Silica-based affinity chromatography | Clotting times in plasma | Genomic | DNA shortens clotting times, increases TG in plasma, promotes FXII activation and FXIa generation in buffer |
| Thrombin generation in PPP | |||||
| FXII activation, FXIIa-dependent and thrombin-dependent FXIa generation in purified systems | |||||
| Bhagirath et al 201556 | HEK297 cells | Silica-based affinity chromatography. | Thrombin generation in PPP | Genomic | All types of DNA enhance TG in plasma |
| Bacteria | Bacterial DNA was purchased. | Mitochondrial | |||
| Bacterial | |||||
| Kokoye et al 201614 | Normal human leukocytes | Phenol-chloroform extraction | Western blot for FXII and PK activation in purified systems | Genomic | DNA enhances FXII and PK activation in buffer and enhances thrombin generation in plasma. |
| Thrombin generation in PPP | |||||
| Noubouossie et al 201724 | Normal human neutrophils | Silica-based affinity chromatography | ELISA for FXIa-C1INH complexes in purified contact system | Genomic | DNA triggers contact activation in buffer and thrombin generation in PFP and PRP |
| Chromogenic assays for FXIa generation in buffer | DNA amplifies FXIIa- and thrombin-dependent FXIa generation in buffer | ||||
| Thrombin generation in PFP or PRP | DNA amplifies TF-initiated TG in plasma | ||||
| Ivanov et al 201757 | Normal human leukocytes | Phenol-chloroform extraction | Chromogenic assays for PK and FXI activation | Genomic | DNA promotes PK (in the presence of HK) and FXI activation |
| Thrombin generation in plasma | DNA initiates thrombin generation in plasma independently of TF, and amplifies TF-initiated TG in plasma |
HK, high-molecular-weight kininogen; PK, prekallikrein; PPP, platelet-poor plasma; PRP, platelet-rich plasma; C1INH, C1 esterase inhibitor; TG, thrombin generation.